All Stories

  1. Pitfalls and biases in neuroepidemiological studies of COVID-19 and the nervous system: a critical appraisal of the current evidence and future directions
  2. Pharmacogenetics of angiotensin modulators according to APOE-ε4 alleles and the ACE insertion/deletion polymorphism in Alzheimer’s disease
  3. Message From the Editors to Our Reviewers
  4. Looking Behind the Curtain: Patient Stratification According to Genetic or Demographic Factors May Yield Unexpected Results in Studies of Neurodegenerative Diseases
  5. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer’s disease
  6. Lifestyle and pharmacological interventions in South America: Potential barriers for recruitment, implementation, and effectiveness
  7. Message From the Editors to Our Reviewers
  8. List of Reviewers
  9. The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All
  10. Acknowledgement
  11. APOE ε4 Carrier Status as Mediator of Effects of Psychotropic Drugs on Clinical Changes in Patients With Alzheimer’s Disease
  12. Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
  13. Message From the Editors to Our Reviewers
  14. Pharmacogenetic Analyses of Therapeutic Effects of Lipophilic Statins on Cognitive and Functional Changes in Alzheimer’s Disease
  15. New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia
  16. The Viability of Treatment Conditioned to the Pathophysiology of Alzheimer’s Disease
  17. Vascular cognitive impairment and dementia: An early career researcher perspective
  18. Message From the Editors to Our Reviewers
  19. List of Reviewers
  20. Acknowledgement
  21. Message From the Editors to Our Reviewers
  22. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer’s Disease and Cognitively Healthy People
  23. Abstract Anne H Berman – incoming ISBM president
  24. Behavioural effects of the ACE insertion/deletion polymorphism in Alzheimer’s disease depend upon stratification according to APOE-ϵ4 carrier status
  25. Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe
  26. Acknowledgements to Reviewers
  27. Swallowing in behavioral variant frontotemporal dementia
  28. Message From the Editors to Our Reviewers
  29. List of Reviewers
  30. Klüver‐Bucy syndrome due to stroke in the left temporal lobe
  31. Vascular cognitive impairment due to dilated perivascular spaces in putamen: Connections with the ventrolateral prefrontal cortex and neurological deficits
  32. Dementia in Latin America: Paving the way toward a regional action plan
  33. Correlates of neuropsychiatric and motor tests with language assessment in patients with Lewy body dementia
  34. Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer’s Disease
  35. Neuropsychiatric feature profiles of patients with Lewy body dementia
  36. Agitation and impulsivity in mid and late life as possible risk markers for incident dementia
  37. The impact of SARS‐CoV‐2 in dementia across Latin America: A call for an urgent regional plan and coordinated response
  38. Acknowledgments
  39. CEREBROSPINAL-FLUID-BASED BIOMARKER EVIDENCE OF AMYLOIDOGENESIS IN DEMENTIA WITH LEWY BODIES DEPENDS UPON APOE-ε4 CARRIER STATUS
  40. PRISON WITHOUT WALLS: A CASE REPORT OF SEMANTIC VARIANT PRIMARY PROGRESSIVE APHASIA
  41. GRIN2A GENOTYPES AND APOE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER’S DEMENTIA BUT NOT FUNCTIONAL OR COGNITIVE RESPONSE TO MEMANTINE
  42. FOOT CLEARANCE WHILE STEPPING-IN-PLACE AS A TOOL TO SALIENT COGNITIVE AND MOTOR OUTPUT DEFICITS IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A PRELIMINARY STUDY
  43. BEHAVIORAL CORRELATES OF CEREBROSPINAL FLUID BIOMARKERS ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  44. Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
  45. Acknowledgements to Reviewers
  46. Acknowledgments
  47. Influence of Socioeconomic Status and Stress Over Quality of Sleep: A Systematic Review
  48. Author Index
  49. Keyword Index
  50. Movement Disorders: Volume 33, Number S2, October 2018
  51. Abstracts
  52. Lifetime Risk Factors for Functional and Cognitive Outcomes in Patients with Alzheimer’s Disease
  53. GENETICALLY MEDIATED LIFETIME RISK FACTORS FOR COGNITIVE AND FUNCTIONAL DECLINE IN PATIENTS WITH ALZHEIMER’S DEMENTIA FROM SÃO PAULO, BRAZIL
  54. APOE-DEPENDENT PSYCHOTROPIC EFFECTS OVER CLINICAL CHANGES IN ALZHEIMER’S DISEASE DEMENTIA
  55. COGNITIVE AND FUNCTIONAL CORRELATES OF CEREBROSPINAL FLUID CONCENTRATIONS OF AMINOACIDS AND MONOAMINE METABOLITES ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  56. COGNITIVE CHANGES ARE PHARMACOGENETICALLY MEDIATED BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN PATIENTS WITH ALZHEIMER’S DISEASE DEMENTIA
  57. Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
  58. Acknowledgement to reviewers
  59. Effects of APOE haplotypes and measures of cardiovascular risk over gender-dependent cognitive and functional changes in one year in Alzheimer's disease
  60. Acknowledgements to Reviewers
  61. ePresentation
  62. ePoster Session
  63. Author Index
  64. Issue Information
  65. Associations of cerebrovascular metabolism genotypes with neuropsychiatric symptoms and age at onset of Alzheimer’s disease dementia
  66. Longitudinal lipid profile variations and clinical change in Alzheimer's disease dementia
  67. Reviewers for International Journal of Stroke 2016
  68. Neurological impressions on the organization of language networks in the human brain
  69. GRIN1 GENOTYPES AND APOE GENE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER'S DISEASE DEMENTIA BUT NOT COGNITIVE OR FUNCTIONAL RESPONSE TO MEMANTINE
  70. EFFECTS OF APOE GENE HAPLOTYPES AND MEASURES OF CARDIOVASCULAR RISK OVER COGNITIVE AND FUNCTIONAL DECLINE IN ONE YEAR IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA
  71. MOTOR ASPECTS OF DAILY LIVING FOLLOW COGNITIVE AND FUNCTIONAL STATUS BUT NOT BEHAVIOURAL SYMPTOMS IN PATIENTS WITH LEWY BODY DEMENTIA SYNDROMES
  72. Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
  73. Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease
  74. Swallowing in primary progressive aphasia
  75. Predictors of Cognitive and Functional Decline in Patients With Alzheimer Disease Dementia From Brazil
  76. Associations of Blood Pressure with Functional and Cognitive Changes in Patients with Alzheimer's Disease
  77. The Controversial Influence of Cerebrovascular Risk Factors over Pathological Mechanisms of Late-Onset Alzheimer's Disease Dementia
  78. Risk factors for cognitive and functional change in one year in patients with Alzheimer's disease dementia from São Paulo, Brazil
  79. Correlations among cognitive and behavioural assessments in patients with dementia due to Alzheimer's disease
  80. Contrasts Between Patients With Lewy Body Dementia Syndromes and APOE-ε3/ε3 Patients With Late-onset Alzheimer Disease Dementia
  81. A patient with agrammatic primary progressive aphasia developing frontotemporal dementia
  82. Pharmacogenetics of cerebrovascular metabolism modulators in dementia due to Alzheimer’s disease
  83. Assessment of sleep satisfaction in patients with dementia due to Alzheimer’s disease
  84. Acknowledgements
  85. Is there correlation between cognition and functionality in severe dementia? The value of a performance-based ecological assessment for Alzheimer’s disease
  86. Brain-Penetrating Angiotensin-Converting Enzyme Inhibitors and Cognitive Change in Patients with Dementia due to Alzheimer's Disease
  87. PHARMACOGENETICS OF BRAIN-PENETRATING ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN DEMENTIA DUE TO ALZHEIMER'S DISEASE
  88. PHARMACOGENETICS OF CHOLESTEROL-LOWERING DRUGS IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE
  89. RISK FACTORS FOR COGNITIVE CHANGE IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE FROM SÃO PAULO, BRAZIL
  90. Caregiver awareness of cerebrovascular risk of patients with dementia due to Alzheimer's disease in São Paulo, Brazil
  91. Abstracts from the 29th CINP World Congress of Neuropsychopharmacology, Vancouver, Canada, 22–26 June 2014
  92. Risk factors for age at onset of dementia due to Alzheimer's disease in a sample of patients with low mean schooling from São Paulo, Brazil
  93. 2013 Reviewer Acknowledgement
  94. Assessment of risk factors for earlier onset of sporadic Alzheimer′s disease dementia
  95. Educational bias in the assessment of severe dementia: Brazilian cutoffs for severe Mini-Mental State Examination
  96. Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease
  97. Cognitive Impairment in Fibromyalgia
  98. Normal pressure hydrocephalus in the spectrum of neurological complications of systemic lupus erythematosus
  99. A patient with primary progressive aphasia developing dementia due to Alzheimer's disease
  100. Impact of Cerebrovascular Risk Factors over Age of Onset of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from Sao Paulo, Brazil (P04.201)
  101. 2012 Annual Meeting Sunday, October 7, 2012Poster Session Abstracts
  102. A topographic study on the evaluation of speech and language in the acute phase of a first stroke
  103. Functional independence and tests of cognitive assessment in patients with Alzheimer's disease
  104. Impact of cardiovascular risk factors over age of Alzheimer's disease onset in patients with low schooling
  105. Impact of schooling and cardiovascular risk factors over the rate of progression of Alzheimer's disease
  106. Twenty-first Meeting of the European Neurological Society 28–31 May, 2011
  107. Global aphasia as a predictor of mortality in the acute phase of a first stroke
  108. Semantic aphasia as a sole manifestation of acute stroke
  109. Preliminary topographic diagnosis of ischemic brain injuries according to speech and language disorders
  110. Short-term prognosis for speech and language in first stroke patients
  111. Hypoglossal nerve palsy as the sole manifestation of spontaneous internal carotid artery dissection
  112. Author Index
  113. Abstracts
  114. 0661 Primitive Neuroectodermal Tumor of the brain presenting with late spinal cord dissemination after surgical treatment and complementary radiotherapy and chemotherapy
  115. 1499 Trends on the use of complementary exams in modern day neurology: how to teach the patient about the tools actually needed for the investigation without conflicting knowledge with popular wisdom